ArriVent BioPharma AVBP
ArriVent BioPharma reported a net loss of $40.31 million for the three months ended Sep 30, 2026.
ArriVent BioPharma (AVBP) filed a 10-Q with the SEC on Nov 9, 2026, 4:21 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001104659-26-124513
- Revenue: $5 million for the three months ended Sep 30, 2026.
- Net loss: $40.31 million for the three months ended Sep 30, 2026.
- Diluted EPS: -$0.81 for the three months ended Sep 30, 2026.
- Cash and equivalents: $113.58 million at Sep 30, 2026.
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new legal mention
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$43.38M | −$52.69M | +18% |
| Net income | −$40.31M | −$49.89M | +19% |
| Operating cash flow | −$40.71M | −$39.58M | −2.9% |
| Cash | $113.58M | $154.68M | −27% |
New legal mentions (1)
- On October 19, 2026, we received a notice from the USPTO that the USPTO has closed prosecution on the merits of the ex parte reexamination and indicating that the USPTO intends to issue a reexamination certificate confirming all claims of the RE '687 Patent subject to ex parte reexamination.